Programmed death ligand ‐1 expression as immunotherapeutic target in sinonasal cancer

ConclusionThe PD‐L1 positivity does not seem to have prognostic value. However, a proportion of patients with sinonasal SCC and ITAC may benefit from therapy with immune checkpoint inhibitors that recently have been approved for clinical application in head and neck cancer.

Source: Head and Neck - January 22, 2018 Category: ENT & OMF Authors: Cristina Riobello, Blanca Vivanco, Sara Reda, Alejandro L ópez‐Hernández, Cristina García‐Inclán, Sira Potes‐Ares, Virginia N. Cabal, Fernando López, José Luis Llorente, Mario A. Hermsen Tags: ORIGINAL ARTICLE Source Type: research